Pharvaris to Highlight Positive Phase 2 Data from RAPIDe-1
ZUG, Switzerland, Feb. 24, 2023 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a clinical-stage company developing novel, oral bradykinin-B2-receptor...
&#x/blog/globe-newswire/templates/topreviews_v1/dleimages/no_icon.gif;
2023-02-24, 18:55
